The US Congress implements a law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities

New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities* Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar companies that relate to the manufacture, marketing, or sale of biologic

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Jones Day (Washington DC)
  • Jones Day (Washington DC)
  • Jones Day (Washington DC)
  • Jones Day (Washington DC)

Citation

Jonathan Berman, Rosanna McCalips, Julia McEvoy, Larissa Bergin, The US Congress implements a law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities, 10 octobre 2018, e-Competitions October 2018, Art. N° 90020

Visites 169

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues